Ivonescimab In Combination With Chemotherapy Approved In Chi

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0

Related Keywords

China , , Prnewswire Akeso Inc , National Medical Products Administration , Showed Clinically Meaningful , Statistically Significant Benefit , Patients Previously Receiving , Adverse Events , Treatment Discontinuation , Oral Presentation , Manuscript Published ,